In this regard, activation of the PGC-1α–FNDC5–irisin axis is an attractive therapeutic target for ameliorating metabolic diseases such as obesity, insulin resistance, and type 2 diabetes mellitus (T2D). Here, FNDC5 is linked to obesity due to melanocortin 4 receptor deficiency.